JCOG

JCOG（日本臨床腫瘍研究グループ）の公式アカウントです。研究結果やイベント情報を発信します。Official account of the Japan Clinical Oncology Group (JCOG), a multicenter clinical study group founded in 1990.

[JCOG @JCOG_official]

#JCOG 「放射線治療グループ治療開発マップ」を更新しました。ぜひご覧ください

🆕治療開発マップ🔎
#放射線治療 #治療開発マップ #JCOG

https://t.co/x3Wgf4dnVx

[Dr Riyaz Shah @DrRiyazShah]

JCOG0802; Complex segmentectomy outcomes were good but higher risk of locoregional relapse. #ASCO26

[Hidehito HORINOUCHI @HHorinouchi]

🆙 #ASCO26 #LCSM Rapid Oral
🔥JCOG0802/WJOG4607L: Complex vs Simple Segmentectomy vs Lobectomy in NSCLC
✅10y OS: comp 83.5%, simp 83.5%, lobec 79.8%
✅Locoregional relapse📈comp seg (HR 2.124)
🎙️Dr. Atsushi Kamigaichi
🔢8009
🔗 https://t.co/t6POkkHgzG
@OncoAlert @Larvol @ASCO @IASLC

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧠📊 #ASCO26 #Sarcoma | JCOG1802 (2ND-STEP)

✔️ Trabe vs Eri vs Pazo in 2L STS (n=120)
📈 mPFS: 2.9 vs 2.2 vs 3.8 m
📈 mOS: 14.7 vs 13.3 vs 15.7 m
📈 DCR: 50% vs 37% vs 65%

🎯 Pazo: most favorable efficacy signal (NS)
⚠️ No new safety concerns; no formal between-arm comparisons
@OncoAlert

[MV Chandrakanth @ChandrakanthMv]

EPISODE-III (JCOG1503C) — ASCO 2026
• Aspirin 100 mg daily for 3 years did not significantly improve DFS in unselected Stage III CRC.
• HR 0.84 with a 3.4% absolute DFS difference favored aspirin, but statistical significance was not reached.
• Toxicity was minimal and major bleeding was uncommon.
• Ongoing biomarker analyses may clarify whether selected molecular subsets derive greater benefit.
Takashima et al. #ASCO2026 #ColorectalCancer #CRC #GIOncology #MVOnco

[Frank Sinicrope, MD @FASinicropeMD]

Adjuvant aspirin for stage III colorectal cancer after curative resection: Primary analysis of the randomized double-blind placebo-controlled phase III trial (EPISODE-III: JCOG1503C). No DFS benefit; PIK3KCA unknown. #ASCO2026

[Armando Orlandi @ArmandOrlandi]

🌊AMBITION / JCOG1919E (#1019, Hara) 🧊

Can atezolizumab thaw “cold” HR+/HER2− aBC? PTX + BEV ± atezo 👥 (n=281)

❌ NEGATIVE primary endpoint: PFS 12.4 vs 11.2 mo, HR 0.88 (p=0.17)
📈 OS only numerically longer (39.1 vs 31.2 mo, HR 0.80), immature
✅ ORR high & equal (~72%)

🧊 IO still wipes out in luminal aBC. The cold stays cold. 🏄

@OncoAlert #ASCO26

[Kazuki Nozawa, MD @kazuki_nozawa]

JCOG1919E (AMBITION)
#ASCO26 @9p2nNkRpjOrdvcw
Adding atezolizumab to paclitaxel + bevacizumab did not significantly improve PFS in patients with HR+/HER2− advanced breast cancer (12.4 vs 11.2 months; HR 0.88; P=0.168).

A numerical improvement in OS was observed (39.1 vs 31.2 months; HR 0.80; P=0.091), with a manageable safety profile consistent with known toxicities.

These findings do not support the routine addition of atezolizumab to paclitaxel + bevacizumab in an unselected HR+/HER2− population.

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌Paclitaxel plus bevacizumab with or without atezolizumab for hormone receptor-positive/HER2-negative advanced breast cancer: JCOG1919E (AMBITION) phase III trial.
Fumikata Hara ✨🎙️ #ASCO26
@OncoAlert #OncoAlertAF

[tatsunori_shimoi 下井辰徳 @shimoi_oncology]

#ASCO26
JCOG1919E AMBITION試験
HR陽性HER2陰性の初回抗がん剤治療としてPTX+BEV±アテゾリズマブの追加を見た医師主導治験。結果としてmPFSは12.4vs11.2カ月 PFSのHR0.876
OSもアテゾリズマブ群に良さげなトレンドはありましたが、有意差なし
両群の免疫学的背景がわかると興味深いです
@9p2nNkRpjOrdvcw

[OncoDaily IO @OncoDailyIO]

𝗔𝗦𝗖𝗢 𝟮𝟬𝟮𝟲 | 𝗝𝗖𝗢𝗚𝟭𝟵𝟭𝟵𝗘 (𝗔𝗠𝗕𝗜𝗧𝗜𝗢𝗡) 𝗧𝗿𝗶𝗮𝗹
At #ASCO26, @9p2nNkRpjOrdvcw colleagues presented results from the phase 3 JCOG1919E (AMBITION) trial evaluating the addition of atezolizumab to paclitaxel plus bevacizumab in HR+/HER2− advanced breast cancer.
📊 𝗞𝗲𝘆 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀:
▪️ Median PFS: 12.4 vs 11.2 months (HR 0.88)
▪️ Central review PFS: 16.7 vs 13.8 months (HR 0.92)
▪️ Median OS: 39.1 vs 31.2 months (HR 0.80)
▪️ ORR: 73.0% vs 71.9%
▪️ No new safety signals identified
🧬 Despite the biologic rationale of combining VEGF inhibition with PD-L1 blockade, the study did not meet its primary endpoint of improving PFS.
💡 These findings highlight the ongoing challenge of overcoming the immunologically "cold" biology of HR+/HER2− breast cancer, although a numerical OS improvement was observed.
#ASCO2026 #AMBITIONTrial

[Nobuhiro Shibata MD, PhD @shibanob]

🎤 #ASCO2026

🇯🇵 JCOG1919E (AMBITION)

A phase III trial evaluating the addition of atezolizumab to paclitaxel (PTX) plus bevacizumab (BEV) in patients with HR-positive, HER2-negative advanced or recurrent breast cancer resistant to endocrine therapy.

📊 The study did not demonstrate an improvement in progression-free survival (PFS). Although overall survival (OS) showed a trend toward prolongation, the difference was not statistically significant.

🌍 Despite being a negative study, it was a highly anticipated trial that attracted considerable international attention and generated important discussion regarding immunotherapy strategies in HR-positive breast cancer.

👏 Congratulations to Dr. Hara on the presentation, and thank you for your tremendous efforts in leading this important study.

#ASCO26 #JCOG1919E #AMBITION #BreastCancer

[OncoDaily GI @OncoDailyGI]

ASCO 2026 | EPISODE-III/JCOG1503C

Atsuo Takashima presented phase 3 data testing low-dose aspirin after curative resection in unselected stage III CRC.

Aspirin + adjuvant chemo did not significantly improve DFS.

3-year DFS:
75.4% placebo vs 78.8% aspirin
HR 0.84; 95% CI 0.65–1.09; p=0.0987
RFS: 77.2% vs 79.5%; HR 0.87
OS: 96.6% vs 95.2%; HR 1.02

Aspirin was well tolerated; biomarker analyses including PI3K/PIK3CA are ongoing.

@oncodaily

https://t.co/HVdPxYLghU

#ASCO2026 #CRC #GIOncology

[Arndt Vogel @ArndtVogel]

Adjuvant aspirin for stage III CRC after curative resection: Primary analysis of the double-blind placebo-controlled phase III trial (EPISODE-III: JCOG1503C)
#ASCO26
👉well tolerated, but no significant benefit in unselected pts in stage III
👉biomarker analysis ongoing
@myesmo @ASCO

[Daisuke Kotani, MD, Ph.D 小谷 大輔 @DaisukeKotani]

#ASCO26 | LBA3508
EPISODE-III: Ph3 adj aspirin for stage III CRC
Aspirin vs placebo
◾️3y-DFS: 78.8% vs 75.4% (HR 0.84, p=0.0987)
◾️3y-OS: 95.2% vs 96.6% (HR 1.02)
👉The addition of aspirin to standard ACT did not improve outcomes in unselected stage III CRC. Biomarker analyses (e.g., PIK3CA, ctDNA) are awaited.
@ASCO @OncoAlert

[Dr Rishabh Jain @DrRishabhOnco]

#ASCO26 🧬

Does aspirin improve outcomes in stage III colon cancer after surgery and chemotherapy?

The phase III EPISODE-III trial randomized 882 patients with resected stage III CRC to:

🔹 Adjuvant chemotherapy + placebo
vs
🔹 Adjuvant chemotherapy + aspirin 100 mg daily for 3 years

🎯 Primary endpoint: DFS

Key results:
📉 3-year DFS
• Aspirin: 78.8%
• Placebo: 75.4%
• HR 0.84 (95% CI 0.65-1.09)
• p=0.099

📉 Overall survival
• HR 1.02
• No OS benefit observed

🩺 Safety:
Aspirin was generally well tolerated with no major new safety signals.

📌 Takeaway:
Low-dose aspirin did not significantly improve DFS in an unselected stage III CRC population.

However, the consistent DFS/RFS trend raises an important question:
Are we studying the wrong population instead of the wrong drug?

Exploratory biomarker analyses, including PI3K/PIK3CA alterations, are ongoing and may help identify a biologically enriched subgroup more likely to benefit.

Precision adjuvant therapy continues to evolve beyond stage alone.

#OncoTwitter #MedTwitter #ColorectalCancer #CRC @ASCO @OncoAlert @myesmo @esmo_open @JCO_ASCO @larvol

📖 Full data presented at ASCO 2026 ⬇️

[tatsunori_shimoi 下井辰徳 @shimoi_oncology]

日本発のJCOG試験としては難解で、
1st stepの時から、これでパゾパニブがfavorableと言えるのかどうか、についてはまだ自分は充分理解できていません
しかし、120名のRCTを完遂している、遠藤先生をはじめとしたJCOG骨軟部腫瘍グループの成果は素晴らしい！！
#ASCO26

[Dr. Cathy Eng @CathyEngMD]

#ASCO26 Abs LBA #3508: EPISODE-III (JCOG 1503C) randomizes ONLY stage III #coloncancer pts to ASA 100 mg x 3 yrs vs. placebo post adjuvant chemo. Primary endpoint = DFS. #cancer #cancerresearch @OncoAlert
Differs vs. ALASCAA trial (Martling et al; NEJM, 2025)
EPISODE-III
👉Stage III colon
👉PIK3CA MT was not required (PIK3CA MT analysis is ongoing)
👉Adjuvant therapy was required
🛑 In unselected patients, ASA 100 mg was not beneficial for DFS

[Kazuki Nozawa, MD @kazuki_nozawa]

ホルモン受容体陽性HER2陰性乳癌においてPTX+BEVにアテゾリズマブの有効性を検証した@JCOG_official @JGbreast JCOG1919E (AMBTION)試験の結果が原先生 @9p2nNkRpjOrdvcw より報告されました。
残念ながら結果はPFSで有意差なく、ネガティブとなってしまいました。しかしながら、OSでは開きがあり、IOの有効性を示唆する傾向があり、今後のフォローアップが望まれます。
#ASCO26

[JCOG @JCOG_official]

#JCOG 論文公開情報📢

#大腸がん グループJCOG2304" 進行横行 #結腸がん に対する結腸部分切除術の有用性に関するランダム化第III相試験"の試験紹介論文がJapanese Journal of Clinical Oncology に掲載されました👇

https://t.co/CYoiJisOM0

#colorectalcancer